In practice
Common mistakes
The eight errors that most often cost Canadian issuers a filing, a window or a deal — each one visible before the money is spent.
1. Float computed on total shares
The most common and most expensive error. Every >10% holder and every director and officer reduces the number. A company that computes float on all shares can believe it has US$140M when it has US$90M.
2. Float volatility ignored
Eligibility measured at today's price is a snapshot, not a fact. If the 60-day low takes you below US$75M, you have a borderline file, and the SEC review period is long enough for the price to move.
3. FPI drift
Foreign private issuerForeign private issuerA non-U.S. issuer where 50% or less of voting securities are held by U.S. residents, or where no U.S. business-contact test is met. Determines which SEC rulebook applies.Read the guide status is lost gradually: a U.S. acquisition, a U.S. listing, a U.S.-based CEO, a shifting shareholder base. Without a quarterly dashboard and the June measurement date in the calendar, the first sign is a change of forms.
4. Auditor not PCAOB-registered
A Canadian auditor without PCAOBPCAOBPublic Company Accounting Oversight Board. An auditor must be registered with it to sign financial statements filed with the SEC.Read the guide registration cannot sign financial statements filed with the SEC. Discovering this at drafting stage adds a full audit cycle to the timeline.
What is not required is a second audit. Where the statements were audited under Canadian GAAS, an uplisting does not force a PCAOBPCAOBPublic Company Accounting Oversight Board. An auditor must be registered with it to sign financial statements filed with the SEC.Read the guide re-audit; the firm needs to be registered and independent. A PCAOB audit is pulled in by a Form S-8, or by losing MJDSMJDSMultijurisdictional Disclosure System — the 1991 SEC / Canadian securities regulators framework that lets Canadian issuers use Canadian disclosure in U.S. offerings.Read the guide status.
5. Underestimating ongoing cost
The first year is visible and budgeted. The second, third and fourth years are not. A realistic recurring range is US$350,000 to US$750,000 before investor relations, and it does not fall as the novelty wears off.
6. Registering without investor relations
A U.S. registration with no U.S. investor communication produces filings and no liquidity. The registration is the licence; the investor work is the market.
7. Assuming the listing follows automatically
Exchange initial standards on price, float and round-lot holderRound-lot holderA holder of at least 100 shares. Exchange initial listing standards test round-lot holders rather than total holders, and Nasdaq requires at least 50% of them to hold US$2,500 or more.Read the guides are separate from MJDSMJDSMultijurisdictional Disclosure System — the 1991 SEC / Canadian securities regulators framework that lets Canadian issuers use Canadian disclosure in U.S. offerings.Read the guide eligibility. NYSE American and Nasdaq both require US$4.00 for all initial listings, with no lower alternative, and Nasdaq requires at least 50% of round-lot holders to hold US$2,500 or more.
Companies that clear US$75M of float routinely fail the US$4.00 price test or the 300–400 round-lot holderRound-lot holderA holder of at least 100 shares. Exchange initial listing standards test round-lot holders rather than total holders, and Nasdaq requires at least 50% of them to hold US$2,500 or more.Read the guide count. On NYSE American the float must be unrestricted publicly held shares, and in an IPO it must come from the offering.
8. Treating a reverse split as a cure
Exchanges have tightened their rules on splits used to cure a bid-price deficiency. A split does not create value, float or holders, and prices commonly drift back down after one.
The trap is specific on Nasdaq: a company that trades below US$1 within 12 months of a reverse splitReverse splitA consolidation that raises the share price and reduces the share count without changing float value. On Nasdaq, trading below US$1 within 12 months of one removes the bid-price cure period.Read the guide gets no bid-price cure period, and delisting proceedings begin immediately. Nasdaq's US$5 million market value of listed securities test likewise carries no cure period after thirty consecutive business days below it.
Canadian exchange approval, and often shareholder approval, are required first. Model the ratio, the holder effect and the earnings-per-share optics before proposing it to a board.
This guide is general information, not advice. Thresholds and forms change; every rule on this site carries a source and a last-verified date, and a determination that matters should be confirmed with qualified U.S. and Canadian counsel.
Rules 2026.11.3 · last verified Nov 19, 2026